This contrasts with studies done on T‐DXd, with results from the DESTINY and DAISY [8, 9, 12] trial demonstrating the efficacy of T‐DXd in both breast and gastric cancers even with low (IHC 1+) HER2 expression. Here, ERBB2 is linked to gastric cancer.